CVRx Q4 revenue rises 4%, beats expectations

CVRx

12/02/2026 21:13

Overview

Medical device company's Q4 revenue rose 4%, beating analyst expectations

Gross margin improved to 86% due to higher selling prices and efficiencies

Outlook

CVRx expects 2026 revenue between $63.0 mln and $67.0 mln

Company anticipates 2026 gross margin between 84% and 86%

CVRx forecasts Q1 2026 revenue between $13.7 mln and $14.7 mln

Result Drivers

SALES TERRITORY EXPANSION - Revenue growth driven by expansion into new sales territories and increased awareness of Barostim therapy

MANUFACTURING EFFICIENCIES - Improved manufacturing efficiencies contributed to higher gross margin

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Beat
$16.02 mln
$15.82 mln (7 Analysts)
Q4 EPS
-$0.46
Q4 Net Income
-$11.93 mln
Q4 Gross Margin
86.00%
Q4 Basic EPS
-$0.46
Q4 Gross Profit
$13.83 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for CVRx Inc is $12.00, about 97.4% above its February 11 closing price of $6.08

Press Release: ID:nGNX46fsB3

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)